TY - JOUR
T1 - Coronary Revascularization in Patients With Cancer
AU - Pushparaji, Bala
AU - Donisan, Teodora
AU - Balanescu, Dinu Valentin
AU - Park, Jong Kun
AU - Monlezun, Dominique J.
AU - Ali, Abdelrahman
AU - Inanc, Ibrahim Halil
AU - Caballero, Jaime
AU - Cilingiroglu, Mehmet
AU - Marmagkiolis, Konstantinos
AU - Iliescu, Cezar
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2023/6
Y1 - 2023/6
N2 - Purpose of review: The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and diseases in improving cardiovascular health in this unique group of patients regardless of cancer type or stage. Recent findings: Novel cancer therapeutics such as immune therapies and proteasome inhibitors have been associated with CAD. Recent stent technologies may safely allow for shorter duration (< 6 months) of dual antiplatelet therapy post-percutaneous coronary interventions. Intracoronary imaging may be useful in the decision making process in terms of stent positioning and healing. Summary: Large registry studies have partially filled a gap left by the lack of randomized controlled trials in the treatment of CAD in cancer patients. Cardio-oncology is gaining traction as a major sub-specialty in the cardiology field given the release of the first European Society of Cardiology — Cardio-oncology guidelines in 2022.
AB - Purpose of review: The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and diseases in improving cardiovascular health in this unique group of patients regardless of cancer type or stage. Recent findings: Novel cancer therapeutics such as immune therapies and proteasome inhibitors have been associated with CAD. Recent stent technologies may safely allow for shorter duration (< 6 months) of dual antiplatelet therapy post-percutaneous coronary interventions. Intracoronary imaging may be useful in the decision making process in terms of stent positioning and healing. Summary: Large registry studies have partially filled a gap left by the lack of randomized controlled trials in the treatment of CAD in cancer patients. Cardio-oncology is gaining traction as a major sub-specialty in the cardiology field given the release of the first European Society of Cardiology — Cardio-oncology guidelines in 2022.
KW - ACS
KW - Acute coronary syndrome
KW - CAD
KW - Cancer
KW - Cardio-oncology
KW - Coronary artery disease
KW - Myocardial infarction
KW - PCI
KW - Radiation
UR - http://www.scopus.com/inward/record.url?scp=85153053938&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153053938&partnerID=8YFLogxK
U2 - 10.1007/s11936-023-00982-9
DO - 10.1007/s11936-023-00982-9
M3 - Review article
C2 - 37143711
AN - SCOPUS:85153053938
SN - 1092-8464
VL - 25
SP - 143
EP - 158
JO - Current Treatment Options in Cardiovascular Medicine
JF - Current Treatment Options in Cardiovascular Medicine
IS - 6
ER -